Paper Details

  1. Home
  2. Paper Details

Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease.

Author: EryavecGoran, HerrmannNathan, LanctôtKrista L, NaranjoClaudio A, van ReekumRobert

Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.
Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This double-blind, randomized, placebo-controlled cross-over study evaluated sertraline (100 mg OD) in 22 nondepressed patients with severe probable AD and significant behavioral disturbance. Eight of 21 (38%) completers responded to sertraline. Drug responsive behaviors included aggression/agitation, irritability and aberrant motor behavior. Low aggression, female gender and large prolactin increase were associated with a better response. Larger randomized controlled trials are needed to clarify the profile of responders.
Paper Details　
Original Abstract of the Article :
BACKGROUND: Indications for serotonergic medications in the treatment of behavioral disorders associated with Alzheimer's disease (AD) remain to be established. METHOD: Sertraline (100 mg OD) was evaluated in a double-blind, randomized, placebo-controlled cross-over study in 22 nondepressed patient...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1002/gps.636

データ提供：米国国立医学図書館（NLM）

Gender, aggression and serotonergic function are associated with response to sertraline for behavioral disturbances in Alzheimer's disease

Alzheimer's disease (AD), a complex and debilitating condition, can be like a desert mirage, distorting reality and challenging both individuals and their caregivers. This study, published in [Journal Name], explores the effectiveness of a medication called sertraline in managing behavioral disturbances associated with AD.

Identifying Factors Influencing Sertraline Response

The researchers, like astute desert explorers, investigated the potential factors influencing the effectiveness of sertraline in treating behavioral disturbances in individuals with AD. They found that several factors, including gender, aggression, and serotonergic function, played a role in determining the effectiveness of sertraline. For example, individuals with lower levels of aggression, female gender, and a larger increase in prolactin levels were more likely to respond positively to sertraline treatment.

Improving Management of Behavioral Disturbances in AD

This research sheds light on the potential benefits of sertraline for managing behavioral disturbances in AD, but also highlights the importance of considering individual factors, such as gender and aggression, when making treatment decisions. This personalized approach, like a carefully crafted desert map, can help tailor treatments to individual needs, potentially improving outcomes for patients with AD.

Dr. Camel's Conclusion

This research, like a shimmering oasis in the vast desert of AD research, provides valuable insights into the potential of sertraline in managing behavioral disturbances associated with this complex condition. The findings underscore the importance of considering individual factors, such as gender and aggression, when determining the appropriate course of treatment. As we continue to search for effective treatments for AD, research like this serves as a reminder that understanding individual differences is crucial to improving patient outcomes and enhancing their quality of life.
Date :
  1. Date Completed 2002-07-30
  2. Date Revised 2022-12-07
Further Info :

Pubmed ID

12112177

DOI: Digital Object Identifier

10.1002/gps.636

Related Literature

Article Analysis
・Effective treatment of alzheimer's disease
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.